The impact of statin therapy on plasma levels of von Willebrand factor antigen Systematic review and meta-analysis of randomised placebo-controlled trials

被引：163

作者：

Sahebkar, Amirhossein ^{[1
,2
]}

Serban, Corina ^{[3
]}

Ursoniu, Sorin ^{[4
]}

Mikhailidis, Dimitri P. ^{[5
]}

Undas, Anetta ^{[6
,7
]}

Lip, Gregory Y. H. ^{[8
]}

Bittner, Vera ^{[9
]}

Ray, Kausik K. ^{[10
]}

Watts, Gerald F. ^{[11
]}

Hovingh, G. Kees ^{[12
]}

Rysz, Jacek ^{[13
]}

Kastelein, John J. P. ^{[12
]}

Banach, Maciej ^{[13
]}

机构：

[1] Mashhad Univ Med Sci, Biotechnol Res Ctr, Mashhad, Iran

[2] Univ Western Australia, Royal Perth Hosp, Sch Med & Pharmacol, Metab Res Ctr, Perth, WA 6009, Australia

[3] Victor Babes Univ Med & Pharm, Discipline Pathophysiol, Dept Funct Sci, Timisoara, Romania

[4] Victor Babes Univ Med & Pharm, Discipline Publ Hlth, Dept Funct Sci, Timisoara, Romania

[5] UCL, Sch Med, Dept Clin Biochem, Royal Free Campus, London, England

[6] Jagiellonian Univ, Coll Med, Inst Cardiol, Krakow, Poland

[7] John Paul 2 Hosp, Krakow, Poland

[8] Univ Birmingham, City Hosp, Ctr Cardiovasc Sci, Birmingham, W Midlands, England

[9] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USA

[10] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Primary Care & Publ Hlth, London SW7 2AZ, England

[11] Univ Western Australia, Sch Med & Pharmacol, Royal Perth Hosp, Lipid Disorders Clin,Cardiovasc Med, Perth, WA 6009, Australia

[12] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands

[13] Med Univ Lodz, Chair Nephrol & Hypertens, Dept Hypertens, PL-90549 Lodz, Poland

来源：

THROMBOSIS AND HAEMOSTASIS | 2016年 / 115卷 / 03期

关键词：

von Willebrand Antigen; statins; cardiovascular diseases; atherosclerosis; thrombosis; DOSE ATORVASTATIN TREATMENT; ENDOTHELIAL FUNCTION; CARDIOVASCULAR-DISEASE; RHEUMATOID-ARTHRITIS; DIABETIC-PATIENTS; FACTOR-VIII; MARKERS; ATHEROSCLEROSIS; INFLAMMATION; FLUVASTATIN;

D O I：

10.1160/TH15-08-0620

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Increased plasma levels of von Willebrand factor antigen (vWF:Ag) are associated with high risk of coronary artery disease. The effect of statin therapy on vWF:Ag levels remains uncertain. Therefore the aim of this meta-analysis was to evaluate the effect of statin therapy on vWF:Ag Levels. A systematic multiple-database search was carried out to identify randomized controlled trials (RCTs) that investigated the effect of statins on plasma vWF:Ag levels. Random-effect meta-analysis of 21 treatment arms revealed a significant decrease in plasma vWF:Ag levels following statin therapy (SMD: -0.54, 95 % CI: -0.87, -0.21, p = 0.001). In subgroup analyses, the greatest effect was observed with simvastatin (SMD: -1.54, 95 % CI: -2.92, -0.17, p = 0.028) and pravastatin (SMD: -0.61, 95 % CI: -1.18, -0.04, p = 0.035), but not with fluvastatin (SMD: -0.34, 95 % CI: -0.69, 0.02, p = 0.065), atorvastatin (SMD: -0.23, 95 % CI: -0.57, 0.11, p = 0.179) and rosuvastatin (SMD: -0.20, 95 % CI: -0.71, 0.30, p = 0.431). The lowering effect of statins on plasma vWF:Ag levels was greater in the subset of studies lasting >= 12 weeks (SMD: -0.70, 95 % CI: -1.19, -0.22, p = 0.005) compared with that of studies lasting <12 weeks (SMD: -0.34, 95 % CI: -0.67, 0.003, p = 0.052). Finally, low-intensity statin therapy was not associated with a significant reduction in vWF:Ag levels (SMD: -0.28, 95 % CI: -0.82, 0.27, p = 0.320), but a significant effect was observed in high-intensity statin trials (SMD: -0.66, 95 % CI: -1.07, -0.24, p = 0.002). This meta-analysis of available RCTs demonstrates a significant reduction in plasma vWF:Ag levels following statin therapy.

引用

页码：520 / 532

页数：13

共 63 条

[1] Statins as immunomodulators in systemic sclerosis [J].